eLife: upcoming articles

Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France Competing interests The authors declare that no competing interests exist. Marta Tormos-Pérez Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France Competing interests The authors declare that no competing interests exist. Sabine Vaur Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France Competing interests The authors declare that no competing interests exist. Amélie Feytout Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France Competing interests The authors declare that no competing interests exist. Julien Jaegy Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France Competing interests The authors declare that no competing interests exist. Dácil Alonso Gil Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France Competing interests The authors declare that no competing interests exist. Stéphanie Vazquez Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France Competing interests The authors declare that no competing interests exist. Karl Ekwall Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden Competing interests The authors declare that no competing interests exist. Jean-Paul Javerzat Institut de Biochimie et Génétique Cellulaires, CNRS-Université de Bordeaux, Bordeaux, France For correspondence



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More